Chebulinic acid is a safe and effective antiangiogenic agent in collagen-induced arthritis in mice
Authors:
Open Access
- 23 November 2020
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 22 (1) , 1-11
Abstract
Background: Although vascular endothelial growth factor-A (VEGF)-induced angiogenesis has been reported to play an important role in the pathogenesis of rheumatoid arthritis (RA), serious side effects, mainly grade 2–3 hypertension, which is commonly observed with currently available anti-VEGF agents, can be detrimental for RA patients due to hypertension and associated cardiovascular complications seen in these patients. Thus, identification of anti-VEGF molecules that do not increase blood pressure could be useful for the treatment of RA. Chebulinic acid (CI), a water-soluble small-molecule tannin, can inhibit the actions of VEGF, and a report suggested that CI might not increase blood pressure due to its compensatory effects on the cardiovascular system. Therefore, the effects of CI on blood pressure in mice and the progression of the disease in a murine collagen-induced arthritis (CIA) model were investigated. Methods: CIA was induced in DBA/1J mice with type II collagen. The effects of CI in these animals were then evaluated by determination of clinical, histopathological, and immunohistochemical parameters. The effects of CI on VEGF-induced proangiogenic genes and signaling pathways were examined in vitro and in vivo. Results: Significant CD31 and VEGF expressions were detected in the synovial tissues of mice with CIA, similar to their expressions observed in human RA patients. However, treatment with CI significantly inhibited paw swelling, decreased the mean articular index and joint pathology scores in these animals through inhibition of VEGF-induced proangiogenic gene expressions and signaling pathways that regulate angiogenesis. Unlike currently used antiangiogenic agents, CI at a dose that inhibits VEGF actions did not increase blood pressure in mice. Conclusion: CI can act as a safe and potent anti-VEGF antiangiogenic agent for the treatment of types of inflammatory arthritis, such as RA.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01HL131405)
This publication has 34 references indexed in Scilit:
- Triphala and Its Active Constituent Chebulinic Acid Are Natural Inhibitors of Vascular Endothelial Growth Factor-A Mediated AngiogenesisPLOS ONE, 2012
- Hypoxia—a key regulator of angiogenesis and inflammation in rheumatoid arthritisNature Reviews Rheumatology, 2012
- Polyphenolic compounds in the fruits of Egyptian medicinal plants (Terminalia bellerica, Terminalia chebula and Terminalia horrida): Characterization, quantitation and determination of antioxidant capacitiesPhytochemistry, 2010
- Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?The Oncologist, 2010
- Collagen‐induced arthritis as a model of hyperalgesia: Functional and cellular analysis of the analgesic actions of tumor necrosis factor blockadeArthritis & Rheumatism, 2007
- Collagen-induced arthritisNature Protocols, 2007
- Suppression of the onset and progression of collagen‐induced arthritis by chebulagic acid screened from a natural product libraryArthritis & Rheumatism, 2005
- Plasticity of endothelial cells: rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lymphoid tissue microenvironmentBlood, 2004
- Animal Models of Arthritis: Relevance to Human DiseaseToxicologic Pathology, 1999
- IN VITRO INHIBITORY EFFECTS OF CHEUBULINIC ACID ON THE CONTRACTILE RESPONSES OF CARDIOVASCULAR MUSCLESClinical and Experimental Pharmacology and Physiology, 1996